The role of global risk assessment in hypertension therapy.
暂无分享,去创建一个
Lawrence Joseph | Guy Tremblay | B. Hemmelgarn | L. Joseph | A. Milot | G. Tremblay | Alain Milot | Brenda Hemmelgarn | S. Grover | S A Grover
[1] D. Maclean,et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[2] L. Coupal,et al. Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol , 2003, Epidemiology.
[3] Jayanti Mukherjee,et al. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. , 2005, The American journal of cardiology.
[4] R B D'Agostino,et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. , 2000, American heart journal.
[5] R. Holman,et al. Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679)) , 2002 .
[6] E. Topol,et al. The rudimentary phase of personalised medicine: coronary risk scores , 2003, The Lancet.
[7] L. Coupal,et al. Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[8] Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. , 2004 .
[9] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[10] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[11] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[12] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[13] R B D'Agostino,et al. Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.
[14] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[15] L. Coupal,et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? , 2000, Circulation.
[16] R. Stevens,et al. UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.
[17] S. Straus,et al. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review , 2001, BMJ : British Medical Journal.
[18] Ralph B D'Agostino,et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. , 2003, JAMA.
[19] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[20] L. Coupal,et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.
[21] R. McPherson,et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[22] D. Jacobs,et al. Lipoprotein‐Cholesterol Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study , 1980, Circulation.